2014―2018年广西柳州市HCV的基因型和1b亚型NS5B区的序列特征

尹琦; 罗洲; 陈钦艳; 杨庆利

doi:10.16462/j.cnki.zhjbkz.2020.10.023

2014―2018年广西柳州市HCV的基因型和1b亚型NS5B区的序列特征

doi: 10.16462/j.cnki.zhjbkz.2020.10.023

尹琦^{1, 2},
罗洲²,
陈钦艳³,
杨庆利^1, ,

1.
530200 南宁, 广西中医药大学, 广西高发传染病中西医结合转化医学重点实验室
2.
545007柳州, 柳州市柳铁中心医院检验科
3.
530028 南宁, 广西壮族自治区疾病预防控制中心, 广西病毒性肝炎防治研究重点实验室

详细信息

通讯作者:
杨庆利, E-mail:eyangql@sina.com

中图分类号: R373.2
计量
- 文章访问数: 232
- HTML全文浏览量: 85
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2019-10-12
- 修回日期: 2020-04-28
- 刊出日期: 2020-10-10

The genotypes and sequence characteristics of NS5B region of subtype 1b among hepatitis C viruses in Liuzhou, Guangxi, from 2014 to 2018

YIN Qi^{1, 2},
LUO Zhou²,
CHEN Qin-yan³,
YANG Qing-li^{1
, ,}

1.
Guangxi Key Laboratory of Translational Medicine for Treating High-Incidence Infectious Diseases with Integrative Medicine, Guangxi University of Chinese Medicine, Nanning 530200, China
2.
Department of Clinical Laboratory, Liuzhou Municipal Liutie Central Hospital, Liuzhou 545007, China
3.
Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning 530028, China

More Information

Corresponding author: YANG Qing-li E-mail:eyangql@sina.com

摘要

摘要: 目的分析2014―2018年广西柳州市丙型肝炎病毒（hepatitis C virus，HCV）的基因型分布和HCV 1b亚型NS5B区的序列特征。方法收集慢性丙型病毒性肝炎患者血清，提取HCV RNA，反转录后用巢式PCR扩增NS5B区序列，测序后构建进化树分析HCV基因型和基因亲缘关系。用聚类分析法对比HCV 1b本地群、非本地群和参照株NS5B区基因和蛋白序列的差异。结果广西柳州市HCV流行的基因型包括1a、1b、2a/c、3a、3b、6a、6c/d和未分型（NT），分别占3.39%、43.01%、0.42%、13.98%、6.99%、28.81%、3.18%和0.21%；HCV 1b亚型中61.6%的病毒与各参照株进化距离均较远，其比例在2014―2018年分别占HCV 1b亚型的69.8%、78.6%、43.3%、47.6%和59.6%；该群HCV的NS5B基因有15个经常性突变位点，可导致NS5B蛋白I2682V和S2755N发生经常性变异。结论广西柳州市HCV流行的主导基因型依次为1b、6a和3a；HCV 1b亚型中的大部分属于本地亲缘性群，该群HCV的NS5B蛋白存在特征性的变异位点并可能影响直接抗病毒药的作用。
- 丙型肝炎病毒 /
- 基因型 /
- HCV 1b /
- NS5B区 /
- 变异
Abstract: Objective To analyze the genotypes distribution of hepatitis C virus(HCV)and the sequence characteristics of NS5B region of HCV subtype 1b from 2014 to 2018 in Liuzhou, Guangxi. Methods HCV RNA was extracted from serum of patients with chronic hepatitis C, and the NS5B gene was amplified by nested PCR after reverse transcription. The genotype and genetic relationship of HCV were analyzed by gene sequencing and constructing gene evolutionary tree. The differences of NS5B gene and protein sequence among local, non-local and reference strains of HCV 1b were compared by cluster analysis. Results The genotypes of HCV epidemic in Liuzhou included 1a, 1b, 2a/c, 3a, 3b, 6a, 6c/d and undermined type(NT), which accounted for 3.39%, 43.01%, 0.42%, 13.98%, 6.99%, 28.81%, 3.18% and 0.21%, respectively. The evolutionary distances for 61.6% of the HCV 1b subtype were far away from those of the reference strain. From 2014 to 2018, the proportion of this group accounted for 69.8%, 78.6%, 43.3%, 47.6% and 59.6% of HCV 1b, respectively. Fifteen frequent point mutations of NS5B gene in this group were determined, which caused I2682V and S2755N frequent mutations of NS5B protein. Conclusions The dominant genotypes of HCV epidemic in Liuzhou, Guangxi are 1b, 6a and 3a. Most of the subtypes of HCV 1b belong to the local genetic group. The NS5B proteins of this group have characteristic mutational sites and may affect the antiviral effect with direct antiviral drugs.
- Hepatitis C virus /
- Genotype /
- HCV 1b /
- NS5B region /
- Mutation

HTML全文

图 1 HCV 1b亚型的基因进化分析

注：▲表示HCV 1a和1b参照株; A~E依次为2014―2018年研究结果; 虚线框内为HCV 1b广西本地亲缘性群。

Figure 1. Phylogenetic analysis of genotype 1b HCV

下载: 全尺寸图片幻灯片

表 1 2014―2018年柳州CHC患者感染HCV基因型分布

Table 1. HCV genotype distribution in CHC patients in Liuzhou from 2014 to 2018

年份	例数[n(%)]
年份	1a	1b	2a/c	3a	3b	6a	6e/d	NT
2014	6(3.6)	86(50.9)	0(0.0)	22(13.0)	7(4.1)	44(26.0)	4(2.4)	0(0.0)
2015	0(0.0)	14(35.9)	0(0.0)	2(5.13)	8(21.0)	11(28.2)	4(10.3)	0(0.0)
2016	2(2.9)	30(42.9)	1(1.4)	9(12.9)	4(5.7)	20(28.6)	3(4.3)	1(1.4)
2017	2(3.4)	21(35.6)	0(0.0)	11(18.6)	4(6.8)	20(33.9)	1(1.7)	0(0.0)
2018	6(4.4)	52(38.5)	1(0.7)	22(16.3)	10(7.4)	41(30.4)	3(2.2)	0(0.0)
合计	16(3.4)	203(43.0)	2(0.4)	66(14.0)	33(7.0)	136(28.8)	15(3.2)	1(0.2)

下载: 导出CSV

参考文献(14)

[1]	Wandeler G, Dufour JF, Bruggmann P, et al. Hepatitis C:a changing epidemic[J]. Swiss Med Wkly, 2015, 145:w14093. DOI: 10.4414/smw.2015.14093.
[2]	Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes[J]. Hepatology, 2015, 61(1):77-87. DOI: 10.1002/hep.27259.
[3]	Lu L, Nakano T, He Y, et al. Hepatitis C virus genotype distribution in China:predominance of closely related subtype 1b isolates and existence of new genotype 6 variants[J]. J Med Virol, 2005, 75(4):538-549. DOI: 10.1002/jmv.20307.
[4]	Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment web resource[J]. Hepatology, 2014, 59(1):318-327. DOI: 10.1002/hep.26744.
[5]	尹琦, 杨庆利, 方钟燎, 等.基于丙型肝炎病毒NS5B区的巢式RT-PCR和基因分型的比较研究[J].中国病原生物学杂志, 2016, 11(8):685-689, 695. DOI: 10.13350/j.cjpb.160803. Yin Q, Yang QL, Fang ZL, et al. A comparison of nested RT-PCR targeting the NS5B region and genotyping of the hepatitis C virus[J]. Journal of Pathogen Biology, 2016, 11(8):685-689, 695. DOI: 10.13350/j.cjpb.160803.
[6]	Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C:an update[J]. Hepatology, 2009, 49(4):1335-1374. DOI: 10.1002/hep.22759.
[7]	Toshikuni N. Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis[J]. Gut Liver, 2017, 11(3):335-348. DOI: 10.5009/gnl15458.
[8]	Bastos JC, Padilla MA, Caserta LC, et al. Hepatitis C virus:promising discoveries and new treatments[J]. World J Gastroenterol, 2016, 22(28):6393-6401. DOI: 10.3748/wjg.v22.i28.6393.
[9]	Ponziani FR, Mangiola F, Binda C, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C[J]. World J Hepatol, 2017, 9(7):352-367. DOI: 10.4254/wjh.v9.i7.352.
[10]	Asselah T. Sofosbuvir for the treatment of hepatit is C virus[J]. Expert Opin Pharmaco, 2014, 15(1):121-130. DOI: 10.1517/14656566.2014.857656.
[11]	Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection[J]. Gastroenterology, 2014, 147(2):359-365. DOI: 10.1053/j.gastro.2014.04.045.
[12]	Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site[J]. Nat Struct Biol, 1999, 6(10):937-943. DOI: 10.1038/13305.
[13]	Pockros PJ. Nucleoside/nucleotide analogue polymerase inhibitors in development[J]. Clin Liver Dis, 2013, 17(1):105-110. DOI: 10.1016/j.cld.2012.09.007.
[14]	阳光, 苏明华, 江建宁, 等.广西地区HCV 1b型感染者NS5B区基因耐药多态性分析[J].临床肝胆病杂志, 2019, 35(5):992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012. Yang G, Su MH, Jiang JN, et al. Resistance-associated variants in the non-structural protein 5B region in patients with hepatitis C virus genotype 1b infection in Guangxi, China[J]. Chin J Clin Hepatol, 2019, 35(5):992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012.